ES2335368T3 - Gen de fusion eml4-alk. - Google Patents

Gen de fusion eml4-alk. Download PDF

Info

Publication number: ES2335368T3
Authority: ES; Spain
Prior art keywords: baselineskip; polypeptide; seq; alk; eml4
Prior art date: 2006-10-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07254044T

Other languages

English (en)

Spanish (es)

Inventor

Hiroyuki Mano

Sadao Kuromitsu

Nobuaki Shindo

Takatoshi Soga

Takashi Furutani

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Astellas Pharma Inc

CureGene KK

Original Assignee

Astellas Pharma Inc

CureGene KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-11

Filing date

2007-10-11

Publication date

2010-03-25

2007-10-11 Application filed by Astellas Pharma Inc, CureGene KK filed Critical Astellas Pharma Inc

2010-03-25 Application granted granted Critical

2010-03-25 Publication of ES2335368T3 publication Critical patent/ES2335368T3/es

Status Active legal-status Critical Current

2027-10-11 Anticipated expiration legal-status Critical

Links

230000004927 fusion Effects 0.000 title claims abstract description 324
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 399
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 390
229920001184 polypeptide Polymers 0.000 claims abstract description 385
102000040430 polynucleotide Human genes 0.000 claims abstract description 259
108091033319 polynucleotide Proteins 0.000 claims abstract description 259
239000002157 polynucleotide Substances 0.000 claims abstract description 259
238000000034 method Methods 0.000 claims abstract description 167
108090000623 proteins and genes Proteins 0.000 claims abstract description 106
238000001514 detection method Methods 0.000 claims abstract description 45
230000000694 effects Effects 0.000 claims description 137
102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 77
238000012360 testing method Methods 0.000 claims description 70
108091000080 Phosphotransferase Proteins 0.000 claims description 69
102000020233 phosphotransferase Human genes 0.000 claims description 69
150000001413 amino acids Chemical class 0.000 claims description 61
239000002773 nucleotide Substances 0.000 claims description 54
125000003729 nucleotide group Chemical group 0.000 claims description 54
101150023956 ALK gene Proteins 0.000 claims description 49
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 43
108091034117 Oligonucleotide Proteins 0.000 claims description 42
102000004169 proteins and genes Human genes 0.000 claims description 42
230000000295 complement effect Effects 0.000 claims description 41
102000039446 nucleic acids Human genes 0.000 claims description 41
108020004707 nucleic acids Proteins 0.000 claims description 41
150000007523 nucleic acids Chemical class 0.000 claims description 41
230000000692 anti-sense effect Effects 0.000 claims description 38
101150068690 eml4 gene Proteins 0.000 claims description 37
101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 claims description 31
102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 claims description 29
230000003321 amplification Effects 0.000 claims description 22
238000012217 deletion Methods 0.000 claims description 22
230000037430 deletion Effects 0.000 claims description 22
238000003199 nucleic acid amplification method Methods 0.000 claims description 22
101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 12
238000003780 insertion Methods 0.000 claims description 8
230000037431 insertion Effects 0.000 claims description 8
238000006467 substitution reaction Methods 0.000 claims description 6
102000001253 Protein Kinase Human genes 0.000 claims description 5
108060006633 protein kinase Proteins 0.000 claims description 5
241000258955 Echinodermata Species 0.000 claims description 3
108091022875 Microtubule Proteins 0.000 claims description 3
102000029749 Microtubule Human genes 0.000 claims description 3
210000004688 microtubule Anatomy 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 26
206010028980 Neoplasm Diseases 0.000 abstract description 95
201000011510 cancer Diseases 0.000 abstract description 66
238000012216 screening Methods 0.000 abstract description 62
239000003814 drug Substances 0.000 abstract description 36
239000013598 vector Substances 0.000 abstract description 35
229940124597 therapeutic agent Drugs 0.000 abstract description 27
239000000523 sample Substances 0.000 abstract description 23
108700020796 Oncogene Proteins 0.000 abstract description 10
102000037865 fusion proteins Human genes 0.000 abstract description 9
108020001507 fusion proteins Proteins 0.000 abstract description 9
210000004027 cell Anatomy 0.000 description 253
108020004414 DNA Proteins 0.000 description 192
241000282414 Homo sapiens Species 0.000 description 122
239000000126 substance Substances 0.000 description 104
101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 77
230000014509 gene expression Effects 0.000 description 77
150000001875 compounds Chemical class 0.000 description 68
238000003752 polymerase chain reaction Methods 0.000 description 64
239000002299 complementary DNA Substances 0.000 description 46
108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
239000000047 product Substances 0.000 description 42
206010058467 Lung neoplasm malignant Diseases 0.000 description 39
230000002401 inhibitory effect Effects 0.000 description 39
201000005202 lung cancer Diseases 0.000 description 39
208000020816 lung neoplasm Diseases 0.000 description 39
230000005764 inhibitory process Effects 0.000 description 35
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
238000006366 phosphorylation reaction Methods 0.000 description 32
108020004459 Small interfering RNA Proteins 0.000 description 30
230000026731 phosphorylation Effects 0.000 description 30
239000003112 inhibitor Substances 0.000 description 27
108020004999 messenger RNA Proteins 0.000 description 26
230000012010 growth Effects 0.000 description 23
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 22
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 22
238000013518 transcription Methods 0.000 description 20
230000035897 transcription Effects 0.000 description 20
230000035578 autophosphorylation Effects 0.000 description 19
239000012634 fragment Substances 0.000 description 18
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 18
239000002904 solvent Substances 0.000 description 18
230000010261 cell growth Effects 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 17
229940126062 Compound A Drugs 0.000 description 16
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
238000003119 immunoblot Methods 0.000 description 16
210000004369 blood Anatomy 0.000 description 15
239000008280 blood Substances 0.000 description 15
238000000338 in vitro Methods 0.000 description 15
239000000243 solution Substances 0.000 description 15
239000000758 substrate Substances 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
239000013604 expression vector Substances 0.000 description 13
230000003834 intracellular effect Effects 0.000 description 13
239000013612 plasmid Substances 0.000 description 13
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
238000002844 melting Methods 0.000 description 12
230000008018 melting Effects 0.000 description 12
239000000203 mixture Substances 0.000 description 12
239000008194 pharmaceutical composition Substances 0.000 description 12
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 12
108010002386 Interleukin-3 Proteins 0.000 description 11
206010036790 Productive cough Diseases 0.000 description 10
210000003802 sputum Anatomy 0.000 description 10
208000024794 sputum Diseases 0.000 description 10
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
238000003757 reverse transcription PCR Methods 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
241001430294 unidentified retrovirus Species 0.000 description 9
206010025323 Lymphomas Diseases 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
241000699660 Mus musculus Species 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000004873 anchoring Methods 0.000 description 7
230000008859 change Effects 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
230000036961 partial effect Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108091081024 Start codon Proteins 0.000 description 6
230000030833 cell death Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000010367 cloning Methods 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000007017 scission Effects 0.000 description 6
238000001890 transfection Methods 0.000 description 6
230000005740 tumor formation Effects 0.000 description 6
206010029260 Neuroblastoma Diseases 0.000 description 5
108020005038 Terminator Codon Proteins 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000000284 extract Substances 0.000 description 5
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
238000011081 inoculation Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
201000005296 lung carcinoma Diseases 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000007170 pathology Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
238000000926 separation method Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000005406 washing Methods 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
230000004544 DNA amplification Effects 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
108010048032 cyclophilin B Proteins 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000009368 gene silencing by RNA Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
-1 isopropylsulfonyl Chemical group 0.000 description 4
238000012332 laboratory investigation Methods 0.000 description 4
230000035772 mutation Effects 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
238000003753 real-time PCR Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
101150039808 Egfr gene Proteins 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
108020004682 Single-Stranded DNA Proteins 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
244000078912 Trichosanthes cucumerina Species 0.000 description 3
235000008322 Trichosanthes cucumerina Nutrition 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
108700021358 erbB-1 Genes Proteins 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000009422 growth inhibiting effect Effects 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
239000013642 negative control Substances 0.000 description 3
230000017066 negative regulation of growth Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000012772 sequence design Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000012096 transfection reagent Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
FTSDLONCFCQDGA-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)OC)=NC=C1Br FTSDLONCFCQDGA-UHFFFAOYSA-N 0.000 description 2
CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 2
HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
208000016718 Chromosome Inversion Diseases 0.000 description 2
238000007400 DNA extraction Methods 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
101000652263 Homo sapiens Protein SOGA1 Proteins 0.000 description 2
101100160997 Mus musculus Rchy1 gene Proteins 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
102100030527 Protein SOGA1 Human genes 0.000 description 2
108091030071 RNAI Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
229940064004 antiseptic throat preparations Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
208000037516 chromosome inversion disease Diseases 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
102000051965 human ALK Human genes 0.000 description 2
239000003906 humectant Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
WIYNWLBOSGNXEH-UHFFFAOYSA-N 4-(2-amino-6,7-dimethoxyquinazolin-4-yl)phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N)=NC=1C1=CC=C(O)C=C1 WIYNWLBOSGNXEH-UHFFFAOYSA-N 0.000 description 1
QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
229940126069 ALK kinase inhibitor Drugs 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920001342 Bakelite® Polymers 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
102100034665 Clathrin heavy chain 2 Human genes 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
102100030115 Cysteine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
206010071975 EGFR gene mutation Diseases 0.000 description 1
101150104134 EML gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710081048 Endonuclease III Proteins 0.000 description 1
241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
108010020195 FLAG peptide Proteins 0.000 description 1
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
101150112014 Gapdh gene Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000003043 HTRF KinEASE-TK Methods 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000946482 Homo sapiens Clathrin heavy chain 2 Proteins 0.000 description 1
101000586290 Homo sapiens Cysteine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
101000800847 Homo sapiens Protein TFG Proteins 0.000 description 1
101000822459 Homo sapiens Protein transport protein Sec31A Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
238000007397 LAMP assay Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
239000012807 PCR reagent Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102100033661 Protein TFG Human genes 0.000 description 1
102100022484 Protein transport protein Sec31A Human genes 0.000 description 1
101150108975 Rhd gene Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
239000004637 bakelite Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
238000012054 celltiter-glo Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000002070 germicidal effect Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
102000043618 human EML4 Human genes 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
201000010893 malignant breast melanoma Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000002493 microarray Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
JXZYNYGTZLAAAU-UHFFFAOYSA-N n-[2-(3-chlorophenyl)ethyl]-2-[[[2-[4-(trifluoromethoxy)phenoxy]acetyl]amino]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1OCC(=O)NCC1=NC(C(=O)NCCC=2C=C(Cl)C=CC=2)=CS1 JXZYNYGTZLAAAU-UHFFFAOYSA-N 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
108700009251 p80(NPM-ALK) Proteins 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000011340 peptidyl-tyrosine autophosphorylation Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
102000005162 pleiotrophin Human genes 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Pathology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

ES07254044T 2006-10-11 2007-10-11 Gen de fusion eml4-alk. Active ES2335368T3 (es)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
JP2006277718		2006-10-11
JP2006-277718		2006-10-11
JP2007-120670		2007-05-01
JP2007120670		2007-05-01
CA2598893		2007-08-24
CA 2598893 CA2598893C (en)	2006-10-11	2007-08-24	Eml4-alk fusion gene

Publications (1)

Publication Number	Publication Date
ES2335368T3 true ES2335368T3 (es)	2010-03-25

Family

ID=39277176

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES07254044T Active ES2335368T3 (es)	2006-10-11	2007-10-11	Gen de fusion eml4-alk.
ES09006058.3T Active ES2515170T3 (es)	2006-10-11	2007-10-11	Gen de fusión EML4-ALK

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES09006058.3T Active ES2515170T3 (es)	2006-10-11	2007-10-11	Gen de fusión EML4-ALK

Country Status (7)

Country	Link
US (7)	US7728120B2 (2)
EP (1)	EP2116553B1 (2)
JP (2)	JP4303303B2 (2)
AT (1)	ATE450547T1 (2)
CA (1)	CA2598893C (2)
DE (1)	DE602007003543D1 (2)
ES (2)	ES2335368T3 (2)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120208824A1 (en)	2006-01-20	2012-08-16	Cell Signaling Technology, Inc.	ROS Kinase in Lung Cancer
PT2450437T (pt) *	2006-04-14	2017-08-25	Cell Signaling Technology Inc	Defeitos de genes e cinase alk mutante em tumores sólidos humanos
ES2458497T3 (es) *	2006-04-14	2014-05-05	Cell Signaling Technology, Inc.	Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) *	2006-04-14	2012-05-01	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) *	2006-10-11	2012-04-10	Astellas Pharma Inc.	Eml4-alk fusion gene
TWI389893B (zh) *	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
EP2255190A4 (en) *	2008-02-12	2011-05-04	Brigham & Womens Hospital	FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER
JP2009219728A (ja) *	2008-03-18	2009-10-01	Daito Giken:Kk	遊技台
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
MX353308B (es)	2008-05-21	2018-01-08	Ariad Pharma Inc	Derivados fosforosos como inhibidores de cinasa.
AU2010248782B2 (en) *	2009-05-15	2015-06-11	Insight Genetics, Inc.	Methods and compositions relating to fusions of ALK for diagnosing and treating cancer
WO2011043220A1 (ja)	2009-10-06	2011-04-14	富士レビオ株式会社	融合遺伝子の測定方法
US9175350B2 (en)	2009-12-22	2015-11-03	Quest Diagnostics Investments Incorporated	EML4-ALK translocations in lung cancer
WO2011102507A1 (ja) *	2010-02-22	2011-08-25	富士レビオ株式会社	癌遺伝子の同定方法、癌遺伝子発現細胞の樹立方法、および癌遺伝子標的薬のスクリーニング方法
US8383793B2 (en)	2010-04-15	2013-02-26	St. Jude Children's Research Hospital	Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
WO2011130635A2 (en) *	2010-04-16	2011-10-20	Response Genetics, Inc.	Primers, probes, methods and kits for the detection of eml4-alk variants
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
CN103052386B (zh)	2010-08-20	2016-03-02	中外制药株式会社	含有四环化合物的组合物
EP2620497B1 (en) *	2010-09-02	2017-10-11	Kurume University	Method for producing circular dna formed from single-molecule dna
JP2014005206A (ja) *	2010-10-22	2014-01-16	Astellas Pharma Inc	アリールアミノヘテロ環カルボキサミド化合物
JP5769952B2 (ja) *	2010-11-12	2015-08-26	株式会社Ｌｓｉメディエンス	Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法
WO2012075318A2 (en) *	2010-12-01	2012-06-07	Cell Signaling Technology, Inc.	Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
RS54189B1 (sr) *	2011-02-02	2015-12-31	Novartis Ag	Postupci za korišćenje inibitora alk
WO2012139134A2 (en) *	2011-04-07	2012-10-11	Coferon, Inc.	Methods of modulating oncogenic fusion proteins
EP2704572B1 (en)	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6066209B2 (ja) *	2011-08-31	2017-01-25	学校法人久留米大学	Ｄｎａ分子の環状化において単分子による環状化ｄｎａのみを選別する方法
PL2838998T3 (pl)	2012-04-18	2018-04-30	Cell Signaling Technology, Inc.	EGFR i ROS1 w nowotworze
WO2013169401A1 (en)	2012-05-05	2013-11-14	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
US9084456B1 (en) *	2012-05-28	2015-07-21	Jack Zemer	Linkage for jewelry components
US9597348B2 (en)	2012-09-06	2017-03-21	Epizyme, Inc.	Method of treating leukemia
CA2894220A1 (en) *	2012-12-21	2014-06-26	Epizyme, Inc.	Dot1l inhibitors for use in the treatment of leukemia
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
US10705087B2 (en)	2013-07-26	2020-07-07	Japanese Foundation For Cancer Research	Detection method for NTRK3 fusion
WO2015064620A1 (ja) *	2013-10-29	2015-05-07	公益財団法人がん研究会	新規融合体及びその検出法
JPWO2015064621A1 (ja) *	2013-10-29	2017-03-09	公益財団法人がん研究会	新規融合体及びその検出法
WO2015111716A1 (ja)	2014-01-24	2015-07-30	公益財団法人がん研究会	新規融合体及びその検出法
TWI831128B (zh)	2014-04-25	2024-02-01	日商中外製藥股份有限公司	以高用量含有４環性化合物的製劑
JP6873698B2 (ja)	2014-04-25	2021-05-19	中外製薬株式会社	４環性化合物の新規結晶
TWI803187B (zh)	2014-08-08	2023-05-21	日商中外製藥股份有限公司	包含４環性化合物的非晶質體之固體分散體及製劑
EP2990493B1 (en)	2014-09-01	2017-05-24	ARKRAY, Inc.	Primer reagent for amplifying alk fusion gene, alk fusion gene amplification reagent kit including the same, and alk fusion gene amplification method and alk fusion gene analysis method using the same
JP7015171B2 (ja)	2016-01-15	2022-02-02	公益財団法人がん研究会	新規融合体及びその検出法
JP6740172B2 (ja) *	2017-05-02	2020-08-12	セル・シグナリング・テクノロジー・インコーポレイテツド	ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
WO2020006314A1 (en) *	2018-06-27	2020-01-02	City Of Hope	Modification of small rnas for therapeutic uses
BR112020025499A2 (pt)	2018-06-29	2021-03-09	Chugai Seiyaku Kabushiki Kaisha	Composição farmacêutica que compreende agente básico pouco solúvel
JP7385191B2 (ja) *	2019-08-30	2023-11-22	学校法人同志社	Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2020156481A (ja) *	2020-04-06	2020-10-01	セル・シグナリング・テクノロジー・インコーポレイテツド	ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
JP7849382B2 (ja)	2021-10-28	2026-04-21	中外製薬株式会社	シロップ剤
AU2023304031A1 (en)	2022-07-04	2025-02-06	Chugai Seiyaku Kabushiki Kaisha	Combination drug
TW202425998A (zh)	2022-08-30	2024-07-01	日商中外製藥股份有限公司	併用醫藥

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6716613B1 (en)	1999-11-11	2004-04-06	Yamanouchi Pharmaceutical Co., Ltd.	Metalloprotease having aggrecanase activity
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
EP1648455A4 (en)	2003-07-23	2009-03-04	Exelixis Inc	MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
PT1660458E (pt)	2003-08-15	2012-04-27	Novartis Ag	2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
JP2008502595A (ja)	2004-03-31	2008-01-31	エグゼリクシス，インコーポレイテッド	未分化リンパ腫キナーゼモジュレータおよびその使用方法
ES2458497T3 (es)	2006-04-14	2014-05-05	Cell Signaling Technology, Inc.	Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
CA2598893C (en) *	2006-10-11	2012-04-10	Astellas Pharma Inc.	Eml4-alk fusion gene
TWI389893B (zh)	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物

2007
- 2007-08-24 CA CA 2598893 patent/CA2598893C/en active Active
- 2007-08-27 US US11/845,498 patent/US7728120B2/en active Active
- 2007-10-11 ES ES07254044T patent/ES2335368T3/es active Active
- 2007-10-11 DE DE200760003543 patent/DE602007003543D1/de active Active
- 2007-10-11 AT AT07254044T patent/ATE450547T1/de not_active IP Right Cessation
- 2007-10-11 EP EP20090006058 patent/EP2116553B1/en active Active
- 2007-10-11 JP JP2007265917A patent/JP4303303B2/ja active Active
- 2007-10-11 ES ES09006058.3T patent/ES2515170T3/es active Active
2008
- 2008-04-10 US US12/100,595 patent/US7605131B2/en active Active
2009
- 2009-02-18 JP JP2009035918A patent/JP5172736B2/ja active Active
- 2009-05-15 US US12/466,920 patent/US7964710B2/en active Active
2011
- 2011-04-13 US US13/086,245 patent/US8197818B2/en active Active
2012
- 2012-05-10 US US13/468,730 patent/US9029521B2/en active Active
2015
- 2015-03-10 US US14/643,181 patent/US9932589B2/en active Active
2017
- 2017-11-13 US US15/810,918 patent/US20180066266A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150184161A1 (en)	2015-07-02
US20100240673A1 (en)	2010-09-23
US9029521B2 (en)	2015-05-12
EP2116553A1 (en)	2009-11-11
US9932589B2 (en)	2018-04-03
US7964710B2 (en)	2011-06-21
JP5172736B2 (ja)	2013-03-27
CA2598893A1 (en)	2008-04-11
EP2116553B1 (en)	2014-07-30
JP2008295444A (ja)	2008-12-11
US7728120B2 (en)	2010-06-01
CA2598893C (en)	2012-04-10
US20090099193A1 (en)	2009-04-16
JP2009100783A (ja)	2009-05-14
US20130158095A1 (en)	2013-06-20
US8197818B2 (en)	2012-06-12
ES2515170T3 (es)	2014-10-29
ATE450547T1 (de)	2009-12-15
DE602007003543D1 (de)	2010-01-14
US7605131B2 (en)	2009-10-20
US20110230545A1 (en)	2011-09-22
JP4303303B2 (ja)	2009-07-29
US20180066266A1 (en)	2018-03-08
US20080090776A1 (en)	2008-04-17

Publication	Publication Date	Title
ES2335368T3 (es)	2010-03-25	Gen de fusion eml4-alk.
EP1914240B1 (en)	2009-12-02	EML4-ALK fusion gene
ES2702305T3 (es)	2019-02-28	Nuevo producto de fusión de FGFR3
AU2013337264B2 (en)	2018-03-08	Novel fusion molecules and uses thereof
ES2660239T3 (es)	2018-03-21	Una mutación de MEK1 que confiere resistencia a inhibidores de RAF y de MEK
JP2018521973A (ja)	2018-08-09	Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
ES2890556T3 (es)	2022-01-20	Combinación de inhibidor de EGFR e inhibidor de MEK para su uso en el tratamiento del cáncer con mutación de NRAS
ES2963934T3 (es)	2024-04-03	Inhibidores de Bcl 2 para uso en el tratamiento de un cáncer mediado por Bcl 2 que porta la mutación Gly101Val
ES2790896T3 (es)	2020-10-29	Mutantes C-RAF que confieren resistencia a los inhibidores de RAF
US20120107299A1 (en)	2012-05-03	Phosphorylation-inhibiting agent or dephosphorylating agent for pten
KR101872468B1 (ko)	2018-06-28	퇴행성 뇌질환의 치료 또는 진단을 위한 ｐａｋ４ 및 ｃｒｔｃ１의 용도
KR101775356B1 (ko)	2017-09-06	Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
WO2012048667A1 (zh)	2012-04-19	表皮生长因子受体的外显子缺失变异体
ES2880085T3 (es)	2021-11-23	Uso de inhibidores de c-met para tratar cánceres que albergan mutaciones met
KR102898242B1 (ko)	2025-12-19	Mig6 돌연변이를 포함하는, EGFR 표적 약물 민감성 예측용 바이오마커
KR20240153453A (ko)	2024-10-23	IGFBP5 발현 억제용 shRNA를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115369163A (zh)	2022-11-22	Ryr2及其下调剂在治疗转移性结直肠癌中的应用
JP2017042111A (ja)	2017-03-02	癌の罹患の有無の判別方法並びに癌の治療及び／又は予防のための医薬組成物
WO2012158880A2 (en)	2012-11-22	Anaplastic thyroid cancers harbor novel oncogenic mutations of the alk gene
WO2004094628A1 (ja)	2004-11-04	イマチニブ耐性フィラデルフィア染色体陽性ヒト急性リンパ性白血病細胞株及びその使用